Search for: "Amgen Inc"
Results 61 - 80
of 698
Sort by Relevance
|
Sort by Date
20 Apr 2023, 8:46 pm
These considerations were evident in the Federal Circuit's decision in Amgen Inc. v. [read post]
31 Mar 2023, 2:48 am
Cir. 2012); Amgen, Inc. v. [read post]
29 Mar 2023, 12:09 pm
ShareDuring oral argument in Amgen Inc. v. [read post]
23 Mar 2023, 11:41 am
In Amgen Inc. v. [read post]
8 Mar 2023, 2:51 pm
” Amgen Inc. v. [read post]
7 Mar 2023, 9:16 pm
Noonan -- The Supreme Court's (re)consideration of the enablement requirement expected in its decision later this year in Amgen v. [read post]
7 Mar 2023, 8:33 pm
by Dennis Crouch The pending Supreme Court case of Amgen v. [read post]
1 Mar 2023, 4:15 am
The United States Supreme Court is set to hear opening arguments in Amgen Inc. v. [read post]
1 Mar 2023, 4:15 am
The United States Supreme Court is set to hear opening arguments in Amgen Inc. v. [read post]
1 Feb 2023, 9:05 pm
As overall M&A slowed considerably in the latter half of the year in particular, healthcare remained a bright spot, with the announcements of two transactions over $15 billion (Johnson & Johnson’s $16.6 billion acquisition of Abiomed and Amgen’s $27.8 billion acquisition of Horizon Therapeutics) and an additional six deals over $3 billion. [read post]
5 Jan 2023, 10:43 am
Supreme Court on the question presented by Amgen Inc. v. [read post]
5 Jan 2023, 10:43 am
Supreme Court on the question presented by Amgen Inc. v. [read post]
29 Dec 2022, 12:10 pm
While some courts have found a plaintiff’s motion for class certification to be deficient where the plaintiff’s expert did not conduct a consumer survey, Amgen Inc. v. [read post]
22 Dec 2022, 7:59 am
Full Scope Enabling Written Description: The court has granted only one petition, Amgen Inc., v. [read post]
21 Dec 2022, 11:57 am
Amgen, Inc., 2020 WL 9432700, at *5 (D. [read post]
7 Dec 2022, 8:00 am
While there, she prosecuted many notable FCA cases including several qui tam cases against National Medicare Care, Inc. [read post]
30 Nov 2022, 2:13 pm
”[6] The Ninth Circuit in In re BofI Holding, Inc. [read post]
27 Nov 2022, 8:10 pm
Paul Berghoff of McDonnell Boehnen Hulbert & Berghoff LLP will moderate a panel consisting of Larry Coury of Regeneron Pharmaceuticals, Inc.; Stephanie Donahue of Sanofi; Henry Hadad of Bristol-Meyers Squibb Co.; and Stuart Watt of Amgen, Inc. that will discuss the issues and arguments concerning the current state of enablement and written description law and where the law may be headed. [read post]
11 Nov 2022, 9:40 am
Cir. 2021); Plexxikon Inc. v. [read post]
6 Nov 2022, 2:18 pm
In Amgen Inc. v. [read post]
